Scientific evidence suggests that quercetin (QUR) has anxiolytic-like effects in experimental animals. However, the mechanism of action responsible for its anxiolytic-like effects is yet to be discovered. The goal of this research is to assess QUR’s anxiolytic effects in mouse models to explicate the possible mechanism of action. After acute intraperitoneal (i.p.) treatment with QUR at a dose of 50 mg/kg (i.p.), behavioral models of open-field, hole board, swing box, and light–dark tests were performed. QUR was combined with a GABAergic agonist (diazepam) and/or antagonist (flumazenil) group. Furthermore, in silico analysis was also conducted to observe the interaction of QUR and GABA (α5), GABA (β1), and GABA (β2) receptors. In the experimental animal model, QUR had an anxiolytic-like effect. QUR, when combined with diazepam (2 mg/kg, i.p.), drastically potentiated an anxiolytic effect of diazepam. QUR is a more highly competitive ligand for the benzodiazepine recognition site that can displace flumazenil (2.5 mg/kg, i.p.). In all the test models, QUR acted similar to diazepam, with enhanced effects of the standard anxiolytic drug, which were reversed by pre-treatment with flumazenil. QUR showed the best interaction with the GABA (α5) receptor compared to the GABA (β1) and GABA (β2) receptors. In conclusion, QUR may exert an anxiolytic-like effect on mice, probably through the GABA-receptor-interacting pathway.
Cancer is the second most killer worldwide causing millions of people to lose their lives every year. In the case of women, breast cancer takes away the highest proportion of mortality rate than other cancers. Due to the mutation and resistance-building capacity of different breast cancer cell lines against conventional therapies, this death rate is on the verge of growth. New effective therapeutic compounds and treatment method is the best way to look out for in this critical time. For instance, new synthetic derivatives/ analogues synthesized from different compounds can be a ray of hope. Numerous synthetic compounds have been seen enhancing the apoptosis and autophagic pathway that directly exerts cytotoxicity towards different breast cancer cell lines. To cease the ever-growing resistance of multi-drug resistant cells against anti-breast cancer drugs (Doxorubicin, verapamil, tamoxifen) synthetic compounds may play a vital role by increasing effectivity, showing synergistic action. Many recent and previous studies have reported that synthetic derivatives hold potentials as an effective anti-breast cancer agent as they show great cytotoxicity towards cancer cells, thus can be used even vastly in the future in the field of breast cancer treatment. This review aims to identify the anti-breast cancer properties of several synthetic derivatives against different breast cancer and multi-drug-resistant breast cancer cell lines with their reported mechanism of action and effectivity.
In recent decades, acceptance of nanoparticles (NPs) in therapeutic applications has increased because of their outstanding physicochemical features. By overcoming the drawbacks of conventional therapy, the utilization of metal NPs, metal-oxide, or metal supported nanomaterials have shown to have significant therapeutic applications in medicine. This is proved by a lot of clinical and laboratory investigations that show improved treatment outcomes, site-specific drug delivery, and fewer side effects compared to traditional medicine. The metal NPs interaction with living cells (animal and plant) showed many ways to develop therapeutic models with the NPs. Despite all of the advancements that science has achieved, there is still a need to find out their performance for long-term use to solve modern challenges. In this regard, the present documentation reviews some potential metals, including silver (Ag), gold (Au), zinc (Zn), copper (Cu), iron (Fe), and nickel (Ni) NPs, as therapeutic agents in various areas such as anticancer, antimicrobial, antidiabetic, and applicable for the treatment of many other diseases. Depending on the outstanding ongoing research and practical trials, metal-based NPs can be considered the hope of prospective modern therapeutic areas.
Viral diseases pose significant threats to aquaculture industries worldwide, including the Australian fish and prawn farming sectors, which contribute over AUD 1.6 billion annually to the national economy. The Australian aquaculture industry relies heavily on wild-caught broodstock for seedstock production, introducing substantial and unprecedented biosecurity risks. This systematic review consolidates current knowledge on the viral pathogens affecting key Australian fish and prawn species, their economic impacts, and the biosecurity measures implemented for mitigation. Notably, viral outbreaks have led to losses exceeding AUD 100 million in some sectors, highlighting the urgent need for improved management. Existing biosecurity strategies, including surveillance systems, molecular diagnostics, and pathogen exclusion protocols, are critically assessed for their effectiveness. Emerging approaches such as genetic resistance breeding, advanced vaccination technologies, and integrated risk management frameworks are also explored. Key knowledge gaps, particularly in the context of emerging viral pathogens and their ecological interactions under changing environmental conditions, are identified as priority areas for future research. This review emphasises the necessity of adopting a multidisciplinary approach to enhance the resilience of Australian aquaculture, advocating for stronger biosecurity frameworks and innovative technologies to mitigate the escalating risks posed by viral diseases.
Inflammatory bowel disease (IBD) encompasses a group of chronic and relapsing inflammatory disorders of the gastrointestinal tract, driven by a multifaceted interplay between genetic predisposition, environmental factors and dysregulated immune responses. Central to its immunopathogenesis is the aberrant activation of pro‐inflammatory cytokine networks, among which interferon‐gamma (IFN‐γ) has been increasingly recognised as a critical mediator of mucosal damage and disease perpetuation. IFN‐γ exerts pleiotropic effects on both innate and adaptive immune compartments, orchestrating a pathogenic immune milieu that disrupts intestinal epithelial integrity and sustains chronic inflammation. Recent therapeutic advances have focused on the modulation of IFN‐γ signalling as a targeted approach to restoring intestinal homeostasis. A growing repertoire of IFN‐γ inhibitors—including neutralising monoclonal antibodies (MAbs), small‐molecule Janus kinase (JAK) inhibitors and bioactive phytochemicals—are being explored for their capacity to attenuate IFN‐γ‐driven inflammatory cascades. These agents offer distinct mechanistic profiles, targeting various nodes of the IFN‐γ axis, and hold significant promise for addressing therapeutic gaps in refractory IBD. This review provides a comprehensive evaluation of emerging IFN‐γ‐targeted therapies, detailing their mechanisms of action, preclinical and clinical efficacy and translational potential. By elucidating the therapeutic landscape of IFN‐γ modulation, this study aims to inform the development of more effective and personalised treatment strategies for patients with IBD.
Metabolic disorders are complex conditions that arise from abnormal biochemical reactions, disrupting normal metabolic processes. The most prevalent metabolic disorders include obesity, Type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), nonalcoholic fatty liver disease (NAFLD), and inflammatory bowel disease (IBD). Despite extensive research, no definitive therapeutic strategy has been established for a complete cure. Emerging evidence suggests that gut microbiome dysbiosis plays a critical role in the pathogenesis of these disorders, as maintaining microbial homeostasis is essential for metabolic health. Short‐chain fatty acids (SCFAs) are a key metabolite produced by gut microbiota and exhibit significant therapeutic potential by serving as an energy source for colonocytes, enhancing gut barrier integrity, and modulating inflammation. Our analysis reveals that targeted microbial modulation, particularly through SCFA‐producing probiotics and prebiotics, consistently benefits host metabolism and reduces systemic inflammation across multiple conditions. This review highlights the importance of gut microbiota as a viable therapeutic target and underscore the need for further clinical trials to validate microbiome‐based interventions in metabolic disease management.